--- title: "Hong Kong stock movement: 160 HEALTH rose 16.25%, AI technology leads market confidence, valuation speculation intensifies!" type: "News" locale: "en" url: "https://longbridge.com/en/news/285469495.md" description: "160 HEALTH rose by 16.25%; China National Pharmaceutical Group rose by 1.02%, with a transaction volume of HKD 56.14 million; Shanghai Pharmaceuticals rose by 0.66%, with a transaction volume of HKD 9.52 million; Baiyunshan had a transaction volume of HKD 3.16 million; GUANZE MEDICAL rose by 1.83%, with a market value of HKD 5.814 billion" datetime: "2026-05-07T01:57:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285469495.md) - [en](https://longbridge.com/en/news/285469495.md) - [zh-HK](https://longbridge.com/zh-HK/news/285469495.md) --- # Hong Kong stock movement: 160 HEALTH rose 16.25%, AI technology leads market confidence, valuation speculation intensifies! **Hong Kong Stock Movement** 160 HEALTH rose by 16.25%. Based on recent key news: 1. On May 6, 160 HEALTH introduced AI intelligent body technology OpenClaw, enhancing the efficiency of medical scenario applications. The AI intelligent body shortened the product iteration cycle by over 60%, driving the stock price up by 16.25%. Source: Zhitong Finance 2. On May 6, 160 HEALTH deepened its focus on the public hospital B-end market through the "platform + AI intelligent body + operation" model, avoiding competition in the C-end and building a moat. This strategy boosted market confidence, leading to a significant rise in stock price. Source: Zhitong Finance 3. On May 6, 160 HEALTH was included in the Hong Kong Stock Connect, with favorable factors driving significant stock price fluctuations. The market is engaged in a tug-of-war between "concept speculation" and "fundamental recovery" regarding its valuation logic, resulting in a stock price increase. Source: Zhitong Finance AI medical concept explosion, market volatility intensified. **Stocks with High Trading Volume in the Industry** China National Pharmaceutical Group rose by 1.02%. Based on recent key news: 1. On May 4, China National Pharmaceutical Group recorded a large transaction involving HKD 37.41 million. The transaction price was 1.3% higher than the previous closing price, pushing the stock price up to HKD 18.72, with a transaction amount reaching HKD 74.80 million, indicating strong buying interest in the stock; 2. On May 4, the active buy-sell ratio for China National Pharmaceutical Group was 40:60, with a net active sell of HKD 7.5269 million. Despite capital outflows, the stock price still rose, indicating market optimism about its future performance; 3. On May 4, the trading volume of China National Pharmaceutical Group reached 3.9963 million shares, showing increased investor attention towards the stock, further driving the stock price up. The Hong Kong stock market has recently seen increased volatility, and risks need to be monitored. Shanghai Pharmaceuticals rose by 0.66%. Based on recent news: 1. On May 5, Goldman Sachs released a research report stating that Shanghai Pharmaceuticals' first-quarter revenue increased by 6.4% year-on-year to RMB 75.3 billion, with profit rising by 6.4% year-on-year to RMB 1.4 billion, and gross margin slightly expanding to 10.4%. Goldman Sachs raised its net profit forecasts for 2026 to 2028 by 5%, 3%, and 3.6% respectively, but maintained a "sell" rating, with a target price raised from HKD 10.3 to HKD 10.63. 2. On May 6, Morgan Stanley released a research report stating that Shanghai Pharmaceuticals' first-quarter revenue and net profit both increased by 6.4% year-on-year, in line with expectations. Morgan Stanley mentioned that Shanghai Pharmaceuticals is negotiating potential business development opportunities for its R&D pipeline with multinational companies in the U.S. and EU, and gave its A-shares a "market perform" rating, with a target price of RMB 18.8. 3. On May 5, Zhitong Finance reported that Shanghai Pharmaceuticals' first-quarter revenue and profit both increased by 6.4% year-on-year, meeting market expectations. Both Goldman Sachs and Morgan Stanley made positive adjustments to its future performance, but Goldman Sachs still maintained a "sell" rating. The overall performance of the pharmaceutical industry remains stable, with limited impact from policy changes Baiyunshan, with a transaction amount reaching HKD 3.16 million. Based on recent key news: 4. On May 2, Guangzhou Pharmaceutical Group held a global investment promotion conference during the Canton Fair, where Baiyunshan Hanfang announced new investment policies and signed multiple international cooperation agreements, accelerating the layout of the international market and enhancing market confidence. 5. On May 4, Wanglaoji's successful expansion in overseas markets, especially its innovative strategies in the UK and Singapore, demonstrated Guangzhou Pharmaceutical Group's positive progress in internationalization, boosting investor confidence in its international strategy. 6. On May 6, Guangzhou Pharmaceutical Group established Guangzhou Pharmaceutical Capital Company to deepen capital operations, further enhance brand value and market competitiveness, and drive stock price increases. The trend of internationalization in the pharmaceutical industry is evident, with policy support. **Stocks ranked among the top in industry market capitalization** Guanze Medical rose by 1.83%. Based on recent key news: 1. On May 4, Guanze Medical Information Industry Company issued an announcement clarifying the deadline for submitting share transfer documents to participate in the annual shareholders' meeting. The new deadline is May 22, 2026, at 4:30 PM. This clarification alleviated any concerns shareholders had regarding the administrative deadline, helping to ensure the correctness of corporate governance and orderly participation in the shareholders' meeting. This announcement was published by the issuer information service of the Hong Kong Stock Exchange. 2. On May 4, in its annual shareholders' meeting notice, Guanze Medical Information Industry Company stated that aside from the change in the deadline, all other information remained unchanged. This clarification helps investors better understand the company's governance structure and the process for participating in the shareholders' meeting. The medical information industry has shown stable performance recently ### Related Stocks - [02656.HK](https://longbridge.com/en/quote/02656.HK.md) - [01099.HK](https://longbridge.com/en/quote/01099.HK.md) - [02607.HK](https://longbridge.com/en/quote/02607.HK.md) - [00874.HK](https://longbridge.com/en/quote/00874.HK.md) - [02427.HK](https://longbridge.com/en/quote/02427.HK.md) ## Related News & Research - [US probing if China firms cut output of containers before pandemic, says CBS](https://longbridge.com/en/news/286944311.md) - [Coffee Prices Rebound on Technical Short-Covering](https://longbridge.com/en/news/286941721.md) - [Obamacare Meltdown? Sharp ACA Enrollment Drop Expected As Pandemic-Era Subsidies End](https://longbridge.com/en/news/287067300.md) - [11:05 ETThe Church of Jesus Christ of Latter-day Saints Commits $25 Million to the UNICEF-led Child Nutrition Fund](https://longbridge.com/en/news/287088476.md) - [08:03 ETNCCN reafirma su compromiso con los recursos para el manejo del malestar relacionado con el cáncer](https://longbridge.com/en/news/287060831.md)